慢性乙型肝炎患者与肝癌患者血清可溶性Fas水平研究

目的：了解可溶性Fas(sFas)在肝癌细胞及慢性肝炎中的作用。方法：采用双抗体夹心ELISA法对18例慢性乙型肝炎（CH）患者、12例肝癌患者（HCC）和6例正常对照者（NC）血清sFas进行检测，并对CH患者血清sFas水平与肝细胞损害程度进行相关性分析。结果：HCC患者血清sFas水平比CH患者及NC组明显升高（均P＜0.01)；CH患者血清sFas水平与NC组比较差异有显著性（P＜0.01)。CH患者血清sFas水平与血清ALT/AST，ALB，PTA呈负相关（P＜0.01)，与血清总胆红素呈正相关（P＜0.01)。结论：sFas可阻止肝癌细胞凋亡的发生，而慢性乙型肝炎患者sFas与肝脏重症程度具有相关性。

A comparative study of serum sFas in patients with hepatocellular cancer and chronic hepatitis]

OBJECTIVE: To study the effects of sFas in hepatocellular cancer (HCC) and chronic hepatitis (CH). METHODS: The serum sFas was detected in 18 patients with HCC, 12 patients with CH and 6 cases of normal control by ELISA. RESULTS: The serum sFas in HCC was obviously increased and had significant difference with the patients of CH and normal control (P < 0.01). The serum sFas had positive correlation with the serum TBIL(P < 0.01), but negative correlation with the ALB, PTA and the ratio of ALT/AST(P < 0.01). CONCLUSIONS: sFas may resist the occurrence of HCC apoptosis. In CH, sFas has correlation with the severity of CH. The role of sFas in viral hepatitis is uncertain.